FY2024 EPS Estimates for ATOS Boosted by Cantor Fitzgerald

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities researchers at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Atossa Therapeutics in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($0.20) per share for the year, up from their prior forecast of ($0.22). The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.21) per share.

Several other research analysts have also recently weighed in on the company. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 8th. HC Wainwright lifted their price objective on shares of Atossa Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Ascendiant Capital Markets increased their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a report on Wednesday, September 11th.

Atossa Therapeutics Trading Down 6.6 %

ATOS stock opened at $1.28 on Monday. Atossa Therapeutics has a 1-year low of $0.65 and a 1-year high of $2.31. The firm has a market cap of $161.03 million, a PE ratio of -5.82 and a beta of 1.23. The business’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $1.37.

Institutional Investors Weigh In On Atossa Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $29,000. Intech Investment Management LLC bought a new position in shares of Atossa Therapeutics in the third quarter worth $29,000. SG Americas Securities LLC raised its stake in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares in the last quarter. Cetera Advisors LLC acquired a new stake in Atossa Therapeutics during the first quarter worth about $72,000. Finally, The Manufacturers Life Insurance Company bought a new position in Atossa Therapeutics in the 3rd quarter valued at about $75,000. 12.74% of the stock is owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.